Talent: Developing Our Competitive Advantage
by Mara Aspinall, Health Catalysts Panelists: Stacie
Mallen, Vice President of Human Resources at Ulthera, Inc.; Brady
Young, VP of HR for TGen, Adrienne Scheck, PhD, Associate Professor of
Neurobiology at Barrow
Neurological Institute; Tom Longstreth, Ventana Medical Systems, Inc., a
member of the Roche Group
Closing Keynote - Dr. Glen Weiss of Cancer Treatment Centers of America
Glen Weiss, MD, MBA
Director of Clinical Research & Medical Oncologist
Western Regional Medical Center
Cancer Treatment Centers of America
The clinical research and trials program at Cancer Treatment Centers of America in Goodyear, Arizona has exponentially grown under the leadership of Dr. Glen Weiss. Join us to learn more about groundbreaking new trials taking place here in our state - trials utilizing chemotherapy and immunotherapy together to harness the body's own immune system. Also, hear about CTCA’s vision for the future of cancer care.
Harry A. George, 2012 Bioscience Leader of the Year
For close to four decades, Harry George has been creating, capitalizing, and operating rapid-growth technology companies.
A quiet, action oriented leader. Harry has consistently driven Arizona’s bioscience and technology sectors forward by acting on his vision with commitment, dedication, and determination.
In recognition of his service and accomplishments, Harry A. George is the 2012 Jon W. McGarity Bioscience Leader of the Year
AHSC: Helping People Live Better Longer
Iron Horse Diagnostics - 2013 AZBio Fast Lane Honoree
Iron Horse Diagnostics was honored with the 2013 AZBio Fast Lane Award from the Arizona Bioindustry Association for Accelerating the Development of New ALS Diagnostic Tests.
Amyotrophic Lateral Sclerosis (also known as ALS or Lou Gehrig’s disease) is a devastating disease that is nearly always fatal within 5 years of onset. Due to similarities in their symptomatic progression is it difficult to differentiate ALS from several other disease mimics (motor neuropathy, progressive muscle atrophy, etc.) until it is too late for intervention to have any real effect. With an earlier diagnosis, and therefore earlier intervention, current clinical care may increase the lifespan of these patients and additional drug therapies that are likely to be introduced to the market could be more rapidly initiated. Not only might life expectancy increase, but patients would be given the chance for a higher quality of life for a longer duration due to more rapid inclusion of the patient into multi-disciplinary care treatment offered at specialized ALS clinics.
2012 Bioscience Company of the Year - Cord Blood Registry
The first cord blood sample ever saved by a family belonged to the son of CBR's Scientific Director.
Two decades later, CBR (Cord Blood Registry) is the largest, most experienced stem cell bank, entrusted by families worldwide.Thanks to expecting families like yours, more than 400,000 children have newborn stem cells saved with CBR. As you decide what's best for your family, it's important to understand the CBR difference in quality and experience. CBR has banked more stem cells than any other family bank and has the most experience helping families use their cord blood for medical treatments.
In October 2012, CBR was named the Arizona Bioscience Company of the Year.